BNGO
Bionano Genomics, Inc.
There isn't enough reported data to score BNGO yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
BNGO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
BNGO's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
BNGO PE Valuation
BNGO has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
BNGO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| -- |
Analysts expect BNGO's losses to shrink, with revenue growing.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
BNGO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$150.60 | +$267.00 |
| Q2 2024 | -$312.60 | -$22.20 |
| Q1 2024 | -$372.60 | -$90.60 |
| Q4 2023 | -$408.60 | -$132.60 |
| Q3 2023 | -$417.60 | -$171.60 |
| Q2 2023 | -$290.40 | -$68.40 |
| Q1 2023 | -$282.00 | -$84.00 |
| Q4 2022 | -$276.00 | -$120.00 |
LLY has the stronger earnings trend. Trailing diluted EPS is down 136% for BNGO versus LLY up 51%.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
BNGO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $8.3M | +12% |
| Q2 2026 | $8.2M | +21% |
| Q1 2026 | $6.7M | +3.6% |
| Q4 2025 | $8M | -2.6% |
| Q3 2025 | $7.4M | +21% |
| Q2 2025 | $6.7M | -13% |
| Q1 2025 | $6.5M | -26% |
| Q4 2024 | $8.2M | -24% |
BNGO's revenue is recovering but still below its 2023 peak: $8M last quarter, up 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -79% | +37 points |
| Q2 2026 | -88% | +28 points |
| Q1 2026 | -118% | +13 points |
| Q4 2025 | -107% | +39 points |
| Q3 2025 | -116% | +607 points |
| Q2 2025 | -116% | +103 points |
| Q1 2025 | -131% | +224 points |
| Q4 2024 | -146% | +87 points |
BNGO's operating margin was −79% last quarter, up 37 points from the same quarter a year ago, near the top of its range since 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over BNGO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over BNGO on profitability, with a higher operating margin.
BNGO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$4.5M | +$1.4M |
| Q2 2026 | -$4.7M | -$1.2M |
| Q1 2026 | -$5.7M | -$3M |
| Q4 2025 | -$4.2M | +$2.3M |
| Q3 2025 | -$5.9M | +$7.4M |
| Q2 2025 | -$3.5M | +$17.5M |
| Q1 2025 | -$2.8M | +$25.4M |
| Q4 2024 | -$6.5M | +$23.3M |
BNGO has burned cash in almost every quarter: −$19M over the past year, against −$19M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over BNGO on cash generation, producing positive trailing cash flow while its opponent burns cash.
BNGO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +445K shares |
| 1 year | +248% | +8.6M shares |
| 3 years | +2388% | +11.5M shares |
| 5 years | +5312% | +11.8M shares |
BNGO has 12M diluted shares, up 248% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over BNGO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
BNGO Net Leverage
BNGO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
BNGO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.2 | Neutral |
| Stochastic | 8.2 | Oversold |
BNGO's weekly RSI is 39 (neutral) and its Stochastic is 8 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
BNGO PE vs Healthcare Sector
BNGO has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
BNGO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.29 | 19% below |
| 20 week MA | $1.24 | 16% below |
| 50 week MA | $1.27 | 18% below |
| 100 week MA | $2.86 | 64% below |
| 200 week MA | $112.3 | 99% below |
BNGO is in a downtrend: it's below all five of its weekly moving averages, and 99% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over BNGO on trend strength, trading above more of its moving averages.
BNGO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $648.0 | $423.0 | -35% |
| 2021 | $423.0 | $1,944.0 | +360% |
| 2022 | $1,944.0 | $912.0 | -53% |
| 2023 | $912.0 | $113.4 | -88% |
| 2024 | $113.4 | $12.6 | -89% |
| 2025 | $12.6 | $1.52 | -88% |
| 2026 YTD | $1.52 | $1.04 | -32% |
BNGO has finished four years in a row lower, and it's down 32% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over BNGO on returns for 2026, with the stronger performance.